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Simple Summary: Immunotherapeutic agents harness the patient’s immune system to fight cancer
cells. Especially immune checkpoint inhibitors, a certain group of immunotherapeutic agents, have
recently improved treatment options for many cancer types. Unfortunately, clinical trials testing
of these agents in pancreatic cancer patients have not confirmed promising results from laboratory
experiments. Several characteristics of pancreatic cancer biology, especially the profound tumour
microenvironment that inhibits the successful identification and elimination of tumour cells by
immune cells seems to be responsible for the lacking efficacy of immunotherapeutics in pancreatic
cancer. We summarise recently published clinical trials investigating immunotherapeutic strategies
in pancreatic cancer patients and available data on how these treatments influence pancreatic cancer
biology. Moreover, we identify potential strategies to improve experimental and clinical studies in
order to generate more conclusive data and improve patient outcomes in the future.
Abstract: To date, extensive efforts to harness immunotherapeutic strategies for the treatment
of pancreatic ductal adenocarcinoma (PDAC) have yielded disappointing results in clinical trials.
These strategies mainly focused on cancer vaccines and immune checkpoint inhibitors alone or in
combination with chemotherapeutic or targeted agents. However, the growing preclinical and
clinical data sets from these efforts have established valuable insights into the immunological
characteristics of PDAC biology. Most notable are the immunosuppressive role of the tumour
microenvironment (TME) and PDAC’s characteristically poor immunogenicity resulting from tumour
intrinsic features. Moreover, PDAC tumour heterogeneity has been increasingly well characterized
and may additionally limit a “one-fits-all” immunotherapeutic strategy. In this review, we first outline
mechanisms of immunosuppression and immune evasion in PDAC. Secondly, we summarize recently
published data on preclinical and clinical efforts to establish immunotherapeutic strategies for the
treatment of PDAC including diverse combinatorial treatment approaches aiming at overcoming
this resistance towards immunotherapeutic strategies. Particularly, these combinatorial treatment
approaches seek to concomitantly increase PDAC antigenicity, boost PDAC directed T-cell responses,
and impair the immunosuppressive character of the TME in order to allow immunotherapeutic agents
to unleash their full potential. Eventually, the thorough understanding of the currently available
data on immunotherapeutic treatment strategies of PDAC will enable researchers and clinicians
to develop improved treatment regimens and to design innovative clinical trials to overcome the
pronounced immunosuppression of PDAC.
Keywords: PDAC; immunosuppression; tumour microenvironment; cancer vaccine; checkpoint
inhibition; translational research
1. Introduction
Many cancer patients have benefited from novel immunotherapeutic approaches, most
notably immune checkpoint inhibitors. This class of drugs harnesses the immune system
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for the fight against aberrant cancer cells by inhibiting co-inhibitory signals (immune check-
points) allowing the undamped response of cytotoxic CD8+ T lymphocytes (CTL) to the can-
cer cells. Unfortunately, patients diagnosed with pancreatic ductal adenocarcinoma (PDAC)
have to date not benefited from these and other immunotherapeutic innovations, suggest-
ing the existence of comprehensive immune escape and immunosuppression mechanisms.
Regarding a projected increase of PDAC cases, PDAC is expected to be the second
most common cause of cancer-related death by 2030 in the United States [1]. Still, thera-
peutic options are very limited, resulting in a 5-year overall survival with optimal care
of 5–9% [2]. Due to the lack of specific symptoms and effective early detection mea-
sures, approximately 80% of patients are diagnosed with locally advanced or metasta-
sised PDAC. Currently, the standard of care for this large group of patients is palliative
chemotherapy with FOLFIRINOX (5-FU, Irinotecan, Leucovorin, and Oxaliplatin), or
Gemcitabine/Nab-Paclitaxel. These therapies moderately improve overall survival to 11.1
months [3] and 8.5 months [4], respectively, in comparison to the previous standard of
Gemcitabine monotherapy (6.8 months). However, not all patients are fit for these therapy
regimens, and often adverse effects significantly reduce the quality of life. A minority
of patients (approximately 20%) is diagnosed with a localised PDAC, being eligible for
surgical removal of the primary tumour (if fit enough for the extensive surgical procedure),
the only potentially curative treatment option [5]. However, even 80% of these patients
who undergo surgical removal of the primary tumour followed by adjuvant chemotherapy
with FOLFIRINOX experience relapse within the first five years after diagnosis, resulting
in an overall median survival of 54.4 months [6]. Taken together, these data underscore the
urgent need to improve therapeutic options for PDAC patients of all stages.
Immune surveillance essentially contributes to the elimination of altered (and poten-
tially malignant) cells and thereby prevents cancer onset under physiological conditions [7].
Moreover, most solid tumours comprise a variety of immune cell populations, providing the
rationale for immunotherapeutic strategies to eliminate or at least control tumour burden.
Accordingly, despite the lack of clinical efficacy to date, immunotherapeutic ap-
proaches represent the largest group of therapies currently under investigation for the
treatment of PDAC patients [8]. Immunotherapeutic approaches under investigation are
based on different mechanisms of action, such as activation of T-cell responses by mon-
oclonal antibodies targeting immune checkpoints, vaccination, or adoptive immune-cell
transfer. Since monotherapeutic strategies often fail, recent approaches aim at combining
different immunomodulating agents, e.g., checkpoint inhibitors with agents that attract
and activate antigen-presenting cells (chemokine agonists, cluster of differentiation 40
(CD40) agonists) or suppress factors favouring immune-suppressive cell signatures in the
tumour microenvironment (TME) of PDAC (chemokine antagonists).
In this review, we outline the diverse mechanisms by which PDACs suppress and
escape the activity of immune cells and summarise recently published data from preclinical
and clinical trials exploring the therapeutic potential of immunotherapeutic strategies for
the treatment of PDAC. As available preclinical and clinical data is rapidly mounting, we
mainly focus on current data from the last three years with a special emphasis on the role of
immune checkpoint inhibitors. Additionally, we outline some translational data obtained
from the evaluation of patients treated with these therapies to identify recurrent patterns
of immunologic responses that may be employed for improved combinatorial regimens.
Finally, we highlight unresolved preclinical and clinical research questions arising from the
latest developments of the field with a focus on standards for the translational evaluation of
patient material, biomarker development, and the role of tumour heterogeneity for tailored
treatment strategies.
2. Mechanisms of Immunosuppression and Immune Evasion in PDAC
Like other solid carcinomas, PDAC is characterised by high tumour heterogeneity,
which refers to the different geno- and phenotypes of the PDAC cells, as well as to the
tumour microenvironment (TME). The latter often comprises more than 80% of the total
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tumour mass and, in addition to a distinct desmoplastic response, a variety of stromal cells,
such as carcinoma-associated fibroblasts (CAF), endothelial cells, and diverse immune cell
populations are found [9]. Both the extent and phenotypes of stromal cells are subject to
high dynamics, as they change during tumourigenesis and in turn critically influence it.
Importantly, a high number of CTL infiltrating the tumour tissue positively correlates
with improved survival of PDAC patients, while a high number of regulatory FOXP3+
T-cells (Treg), functionally suppressing the activity of effector T-cells, correlates with poor
outcomes [10]. Additionally, long-term survivors of PDAC exhibited a more diverse T-cell
receptor (TCR) repertoire reflecting a T-cell response to multiple tumour antigens [11].
In order to successfully induce T-cell mediated elimination of cancer cells, several
steps of the cancer-immunity cycle resulting in CTL activation are necessary. These have
been comprehensively characterised by Chen et al. [7]. Tumour-specific (neo)antigens are
required that allow the identification of aberrant tumour cells by immunosurveillance
through resident antigen-presenting cells (APC). Typically, these antigens arise from the
expression of mutated or aberrantly expressed genes and are released upon cancer cell
death. To provoke proper CTL priming, antigens must be presented by dendritic cells
via MHC I and II complexes. Then, T-cells interact with antigen-presenting cells (APC)
resulting in their activation and proliferation if sufficient co-stimulatory signals are present.
CTL traffic to the tumour site, infiltrate the tumour site and invade the tumour tissue,
where they identify tumour cells. Finally, CTL eliminates tumour cells [12].
Even though PDAC tissues comprise T-cell populations to varying amounts, it is
meanwhile well appreciated that PDAC evades T-cell mediated cytotoxicity and hampers
the activation of adaptive immunity by different means. Thus, immune evasion starts right
from the beginning of tumourigenesis as PDAC harbours a comparatively low tumour
mutational burden compared to other cancers such as melanoma [13]. This results in
a smaller number of neoantigens from aberrantly transcribed genes available as a start-
ing point for an adaptive immune response. In terms of survival, a higher number of
tumour-specific neoantigens correlates with a better prognosis in PDAC patients when
accompanied by simultaneous CTL infiltration [11]. Additionally, PDAC downregulates
the expression of HLA class I molecules and thus hides from identification by APC and
T-cells [14]. An important immune evasion strategy in PDAC can be also seen in the
pronounced desmoplastic stroma. CAF which are the most abundant inflammatory stroma
cell population in PDAC release high amounts of extracellular matrix (ECM) proteins on
the one hand [15] and a plethora of immunosuppressive factors on the other hand. This and
a poor vascularisation of the tumour provide an efficient physical barrier characterised by
increased interstitial fluid pressure [16] preventing the infiltration, expansion, and activity
of T-cells in close proximity of PDAC cells [9]. This is further supported by the suppression
of homing-receptors that allow T-cells to attach to the vessel wall and migrate into the
tissue [17]. Finally, CTL that have eventually managed to enter the tumour stroma are
faced by inhibitory signals released by a variety of other immunosuppressive cells, such as
Treg, myeloid-derived suppressor cells (MDSCs) and M2-macrophages [18]. Altogether,
these stromal cells dampen activity and expansion of T-cells, e.g., by secretion of inhibitory
cytokines and chemokines (IL-4, IL-10, IL-13, IL-13, IL-17, transforming growth factor-beta
(TGF-β)), remodelling of the ECM or by upregulation of immune checkpoints such as pro-
grammed cell death 1 ligand 1 (PD-L1) thereby preventing successful elimination of tumour
cells [19]. In the latter context, it is important to note that in PDAC PD-L1 is predominantly
expressed by stromal cells, e.g., macrophages [20,21]. Overall, PDAC is characterised by a
variety of different immune evasion and immunosuppression strategies, and one of the
major challenges is to identify the most prominent strategy in each individual patient in
order to select the most effective treatment.
3. Strategies for Immunotherapy in PDAC
The existing data support the rationale to develop immunotherapeutic regimens that
increase the number and activity of tumour infiltrating lymphocytes (TIL) to elicit a potent
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anti-tumour T-cell response in PDAC patients. For this purpose, different strategies have
been developed and explored for their efficacy in preclinical and clinical studies (Figure 1).
Figure 1. Therapeutic strategies to target immunosuppressive components of the TME in PDAC. Ab-
breviations: Extracellular matrix (ECM); cancer associated fibroblasts (CAF); regulatory T-cells (Treg);
tumour associated macrophages (TAM); dendritic cells (DC). Figure created with BioRender.com.
3.1. Cancer Vaccines for Treatment of PDAC
Applied as cancer therapy, cancer vaccines aim at the delivery of tumour-specific
antigens to elicit a specific and strong T-cell mediated anti-tumour response whilst not
inducing autoimmunity. The main obstacles towards an effective cancer vaccination
strategy have been the choice of appropriate antigen(s), effective adjuvants, the mode of
application [22], and combinatorial strategies. Accordingly, multiple peptides or whole
cell-based tumour vaccines applied as single agents or in combination with conventional
chemotherapy or additional treatment modalities have been explored for the treatment of
PDAC. Antigens used for vaccination purposes have been, i.e., Mesothelin, mutated KRAS,
Vascular Endothelial Growth Factor Receptors 1 and 2 (VEGFR1, VEGFR2), Kinesin-like
Protein KIF20A and Wilms Tumour Protein 1 (WT1) [23–25].
GVAX is a cancer vaccine consisting of irradiated granulocyte-macrophage colony-
stimulating factor (GM-CSF) secreting allogeneic pancreatic tumour cells. The induction of
anti-tumour immunity by vaccination with irradiated GM-CSF expressing tumour cells
had been explored preclinically in animal models for other cancers including melanoma
and prostate cancer [26,27] and a pancreas-specific vaccine entered several clinical trials
for evaluation of safety and efficacy. Translational data from a phase II clinical trial
assessing GVAX alone or in combination with oral or intravenous cyclophosphamide
administered perioperatively (first dose as neoadjuvant and additional doses as adjuvant
treatment) in patients with resectable PDAC confirmed immunological effects of GVAX
activating multiple immune cell populations in the tumour tissue of surgically resected
specimens [28]. Tertiary lymphoid structures histologically resembling lymph nodes
formed after GVAX treatment in the TME. On the one hand, GVAX treatment increased
the number of Interferon-γ (INF-γ) secreting effector TIL, on the other hand also Treg
increasingly infiltrated the TME upon treatment. Moreover, the expression of the immune
checkpoint proteins programmed death protein 1 (PD-1) and its ligand PD-L1 increased in
the tertiary lymphoid infiltrates but positively correlated with overall survival [28]. Final
data from this phase II clinical trial reported a positive trend in mean overall survival (mOS)
for patients treated with neoadjuvant GVAX alone (35.0 months compared to 24.8 months
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in historical controls) in comparison with patients who were additionally treated with
cyclophosphamide (mOS 15.4 and 16.5 months) [29]. Moreover, the formation of tertiary
lymphoid structures in the TME positively correlated with mOS suggesting a dominating
role of the induced anti-tumour immunogenic activity over Treg invasion and increased
immune checkpoint expression [29]. Of note, the trial was not powered for statistical
comparison of treatment arms.
A second phase II clinical trial assessed GVAX in combination with low dose cyclophos-
phamide as a T-cell activity modulating agent alone or in combination with live attenu-
ated mesothelin-expressing Listeria monocytogenes (CRS-207) for treatment of metastatic
PDAC [30]. GVAX alone did not improve mOS. However, the addition of CRS-207 im-
proved the mOS in this heavily pre-treated collective from 3.9 to 6.1 months warranting
further clinical investigation [30]. A subsequent phase IIb study evaluating these results in
a three-arm multicentre design with a larger cohort of patients (n = 213) did not confirm
the initial positive results for a combination of GVAX and CRS-207 and this regimen did
not outperform conventional chemotherapy [31]. Interestingly, translational research ac-
companying both trials identified two prognostic and predictive signatures of circulating
immune-cells (CD8+CD45RO-CCR7-CD57+ and CD14+CD33+CD85j+) by multiplex flow
cytometry and prospectively validated them. However, the functional relevance of these
cell populations remains unclear [32].
Another vaccine approach for PDAC treatment is Algenpantucel-L, also known as the
HAPa cancer vaccine, consisting of two allogeneic pancreatic cancer cell lines expressing
the murine a(1,3)GT gene. Mechanistically, Algenpantucel-L aims at exploiting hyperacute
rejection to murine proteins to induce a strong immune reaction towards PDAC peptides.
This agent was clinically evaluated as part of a neoadjuvant treatment strategy in a phase
III clinical trial (n = 303) adding it to a neoadjuvant standard of care chemotherapy and
chemoradiation for the treatment of borderline resectable or locally advanced unresectable
PDAC [33]. In contrast to promising data from a previous phase II clinical trial [34],
the addition of Algenpantucel-L did not improve overall survival in this larger patient
cohort. In terms of operability of the tumour, no significant differences were observed in
patients receiving standard of care neoadjuvant treatment only or additional Algenpantucel-
L (26% and 23%, respectively). Regarding the subgroup of patients who underwent
surgical resection of the tumour, also no statistical differences in OS were observed (29.9 vs.
27.1 months). Unfortunately, no translational data was published to allow the assessment
of immunological impacts of Algenpantucel-L treatment.
Researchers also evaluated tumour vaccination using OCV-C01, a peptide-based
vaccine combining epitopes from KIF20A, VEGFR1, and VEGFR2, in PDAC patients. In
a single-arm, open-label phase II trial with 30 participants the vaccine was evaluated in
combination with Gemcitabine as an adjuvant therapy in patients with resected PDAC [23].
Translational data collected in this trial revealed a tendency towards longer survival in
patients with specific CTL KIF20A peptide responses or detectable protein expression of
KIF20A in surgically resected specimens. However, these results were not significant and
due to the trial design, a potential benefit of the addition of OCV-C01 to Gemcitabine was
difficult to assess.
Since KRAS is the most abundant mutated oncogene in PDAC found in approximately
90% of specimens, it represents an attractive target for tumour vaccination. Palmer et al.
evaluated a KRAS-targeted peptide vaccine consisting of seven synthetic KRAS peptides
representing the most common mutations found in PDAC (TG01/GM-CSF) in combina-
tion with Gemcitabine as an adjuvant treatment for stage I or II KRAS mutant PDAC
in a phase I/II single-arm clinical trial [24]. The mean overall survival was 33.3 months
compared to historical data sets evaluating Gemcitabine monotherapy (with mOS 17.1–
26.5 months). Immune activation levels towards the provided antigens were evaluated by
delayed hypersensitivity testing and in vitro T-cell assays from longitudinally collected
blood samples. More than 90% of PDAC patients responded with either a positive immune
response in delayed hypersensitivity testing or increased T-cell proliferation after stimu-
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lation with TG01/GM-CSF in vitro providing experimental evidence for the underlying
therapeutic rationale.
Although several additional cancer vaccine strategies have been explored in clinical
trials, none of them has significantly improved the survival and prognosis of PDAC
patients [35–38]. One explanation might be that boosting of effector T-cells alone is not
sufficient to overcome the existing immunosuppression in PDAC TME. Thus, more recent
therapeutic approaches explore the efficacy of cancer vaccines combined with immune
checkpoint inhibitors, which are outlined in the next section.
3.2. Immune Checkpoint Inhibitors for PDAC Treatment
Despite great hopes, checkpoint inhibitors targeting either PD-1, PD-L1 or cytotoxic
T-lymphocyte-associated protein 4 (CTLA-4) applied as monotherapies have not yielded
clinical improvements for PDAC patients in contrast to therapeutic successes in other
cancers [39–42]. Thus, further efforts have focussed on the combination of checkpoint in-
hibitors with other therapeutic strategies, e.g., with conventional chemotherapeutic agents.
Rationally, this combinatorial approach is based on a potential pro-immunogenic effect
of chemotherapy exerted by increased release of tumour antigens and induction of an
inflammatory milieu upon rapid cell death which is facilitated by a profound depletion of
MDSCs and Treg from peripheral blood and tumour sites [43–45]. However, in the clinical
setting, the combination of the CTLA-4 inhibitor Tremelimumab with Gemcitabine [46] or
the combination of the PD-1 inhibitors Nivolumab or Pembrolizumab with Gemcitabine
and Nab-Paclitaxel did not relevantly improve outcomes of PDAC patients in phase I clini-
cal trials [47,48]. Wainberg et al. provided translational data on the effects of Nivolumab
on immune cell populations in PDAC patients demonstrating that CD4+ and CD8+ T-cell
populations in peripheral blood increasingly proliferated after exposure to Nivolumab as
reflected by antigen Ki-67 (Ki-67) positivity. Additionally, T-cell proliferation positively
correlated with clinical outcomes. However, a comparison of pre- and on-treatment biop-
sies by immunohistochemistry (IHC) revealed no changes in T-cell populations within the
tumour hinting at a T-cell activating effect in the periphery but at a lack of T-cell infiltration
into the tumour site [47].
To overcome the clinical inefficacy of checkpoint inhibitors for the treatment of PDAC,
multiple combinatorial approaches to harness T-cell mediated responses have been clini-
cally investigated. These include combinations of two checkpoint inhibitors simultaneously
targeting the PD-1, PD-L1, and CTLA-4 axes (or triple therapy with stereotactic radiation),
combined with small molecule inhibitors (i.e., TGF-β receptor 1 kinase or Bruton tyrosine
kinase (BTK) inhibitors), combined with an oncolytic virus, combined with chemokine
antagonists, with CD40 agonists or with cancer vaccines. This overview underscores
the diversity of therapeutic approaches being used in the clinical trial landscape to over-
come immunosuppression in PDAC patients, which is even broader considering ongoing
or abstracted clinical trials (Table 1). These include combinations with IL-6 antagonist
(NCT04258150), irreversible electroporation (NCT04212026), personalized tumour vaccines
(NCT04161755, NCT03806309), a stimulator of interferon genes (STING) agonistic vaccine
(NCT03010176), an inducible T-cell costimulator kinase inhibition (ICOS) targeted antibody
(NCT03829501), kinase inhibitors (NCT04820179; NCT04820179), and CD73 antagonists
(NCT03806309).
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Table 1. Selected ongoing clinical trials investigating novel immunotherapeutic treatment strategies for PDAC. Abbrevi-
ations: (CY) Cyclophosphamide; (5-FU) 5-Fluorouracil; (Gem) Gemcitabine; (ICOS) Inducible T-cell costimulator kinase
inhibition; (IRE) Irreversible electroporation; (MIS-MWA) Minimally invasive surgical microwave ablation; (Nab-Pacli)
Nab-Paclitaxel; (RT) Radiotherapy; (STING) Stimulator of interferon genes.
Mechanism Target Compound Combination Phase Identifier
Chemokine
antagonism
IL-2 XB2001 Irinotecan, 5-FU, Leucovorin I/II NCT04825288
IL-6 Siltuximab Spartalizumab I/II NCT04191421
CSF1 ARRY-382 Pembrolizumab I/II NCT02880371
IL-1β Canakinumab Nab-Pacli, Gem, Spartalizumab I NCT04581343
CD73 CPI-006 Ciforadenant or Nivolumab I NCT03454451
Immunostimulatory
agonism
CD40 CDX-1140 CDX-301 II NCT04536077
CD40 ABBV-927 Budigalimab, mFOLFORINOX II NCT04807972
IL-12 M9241 M7824 or M7824, RT I/II NCT03849469
STING MK-1454 Pembrolizumab I NCT03010176
Vaccination
Individual TA RO7198457 Atezolizumab, mFOLFIRINOX I NCT04161755
Multiple Tas GVAX CY, Pembrolizumab, IMC-CS4 Early I NCT03153410
Multiple TAs GVAX CY or CY, Nivolumab or CY,Nivolumab, Urelumab I/II NCT02451982
Multiple TAs GVAX CY, Nivolumab, RT II NCT03161379
Multiple TAs GVAX CY, Pembrolizumab, RT II NCT02648282











Alone or CY i.v. or CY orally II NCT01088789
Ten TAs OSE2101 Alone or Nivolumab II NCT03806309
Oncolytic virus Cancer Cell OH2 Herpes simplexvirus I/II NCT04637698
Cancer Cell Talimogenelaherparepvec I NCT03086642
Cancer Cell TBI-1401(HF10) Nab-Pacli, Gem, S-1 I NCT03252808
Immune checkpoint
inhibition
PD-1 Durvalumab Plerixafor II NCT04177810
PD-1 Dostarlimab Niraparib, RT II NCT04409002
PD-1 Camrelizumab Gem, MIS-MWA II NCT04156087
PD-1 Cemiplimab Nab-Pacli, Gem II NCT04498689
PD-1 Pembrolizumab RT I/II NCT02305186






PD-1 Pembrolizumab Azacitidine II NCT03264404
PD-1 Nivolumab Losartan, FOLFIRINOX, RT II NCT03563248
PD-1 Nivolumab IRE II NCT04212026
PD-1 Nivolumab None or IRE or IRE, TLR-9 I NCT04612530
PD-1 Nivolumab Nab-Pacli, Gem, Paricalcitol I NCT03519308
PD-1 Nivolumab Gem, S1 II NCT04377048
PD-1 Nivolumab RT or RT, Ipilimumab II NCT02866383
PD-1+CTLA-4 Nivolumab,Ipilimumab RT II NCT04361162
PD-1+CTLA-4 Nivolumab,Ipilimumab RT, Tocilizumab II NCT04258150
PD-1+CTLA-4 Nivolumab,Ipilimumab RT, Nab-Pacli, Gem I/II NCT04247165
PD-1+CTLA-4 Nivolumab,Ipilimumab RT II NCT03104439
PD-1+CTLA-4 Nivolumab,Ipilimumab CRS-207 or CRS-207, GVAX, CY II NCT03190265
PD-1+CTLA-4 Nivolumab,Ipilimumab Maraviroc I NCT04721301
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Table 1. Cont.
Mechanism Target Compound Combination Phase Identifier












or Nab-Pacli, Gem, Tocilizumab
I/II NCT03193190
PD-L1 Atezolizumab Cabozantinib II NCT04820179
PD-L1+TGF-β SHR-1701 Nab-Pacli, Gem Ib/II NCT04624217
ICOS KY1044 Alone or Atezolizumab I/II NCT03829501
Two recently published clinical trials investigated checkpoint inhibition with Durval-
umab (PD-L1 inhibitor) alone or in combination with Tremelimumab s(CTLA-4 inhibitor)
for the treatment of recurrent or metastatic PDAC patients with [49] or without additional
stereotactic body radiation [50]. The dual combination without additional radiation did
not improve outcomes in a phase II study with 65 participants. Both experimental arms
achieved an mOS of 3.6 and 3.1 months for Durvalumab alone or Durvalumab plus Treme-
limumab, respectively [50]. In a phase I clinical trial with 58 participants, the addition of
stereotactic body radiation to either Durvalumab monotherapy or combination therapy
with Durvalumab and Tremelimumab resulted in a very modest clinical benefit for patients
with metastatic PDAC treated with at least one line of previous systemic therapy [49].
As observed in other clinical trials investigating checkpoint inhibitors in PDAC patients,
analysis of paired biopsies obtained at baseline and on treatment revealed a non-significant
increase in CD3+ and CD8+ T-cells within the tumour. However, this did not correlate
with outcome parameters and as it was only determined in five patients, the validity of
this finding is quite limited.
TGF-β is a key player involved in creating and maintaining an immunosuppressive
TME in PDAC, e.g., by inducing transdifferentiation and ECM production in CAF and
inhibiting Granzyme B mediated T-cell cytotoxicity [51]. Based on these findings, com-
bined TGF-β and PD-L1 inhibition was evaluated in a mouse model of immune excluded
tumours and resulted in an increased invasion of CTL and tumour shrinkage [52]. These
preclinical datasets supported the rationale for the combined inhibition of TGF-β and
immune checkpoints for the treatment of PDAC. Melisi et al. investigated this therapeutic
strategy combining the TGF-β receptor I kinase inhibitor Galunisertinib with PD-L1 in-
hibitor Durvalumab in 32 patients with metastatic or recurrent PDAC who had obtained
up to two previous lines of therapy [53]. Combined treatment resulted in an overall re-
sponse rate (ORR) of 3.1%, a disease control rate (DCR) of 25% and an mOS of 5.72 months.
Importantly, PD-L1 expression did not correlate with the therapeutic response highlighting
the complexity of biomarker identification for patient stratification.
Similarly, BTK signalling contributes to the generation of the immunosuppressive TME.
Mechanistically, BTK signalling is involved in the polarisation of macrophages towards
an M2-phenotype. Tumour-associated macrophages (TAM) often exhibit an immunosup-
pressive M2-subtype which is characterised by secretion of chemokines and cytokines
dampening T-cell activity, facilitating polarisation of Treg, promoting angiogenesis, and
inducing ECM production by CAF [54]. In a mouse model of PDAC, treatment with a
BTK inhibitor increased the number of tumour-infiltrating CD8+ T-cells and resulted in
tumour shrinkage. Antibody-mediated depletion of CD8+ T-cells reversed the anti-tumour
effect of the BTK inhibitor and thus underscored the importance of CD8+ T cells for this
therapeutic strategy [55]. Additionally, BTK signalling mediates desmoplasia of PDAC
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adding another rationale for BTK inhibition in PDAC treatment [56]. However, combined
treatment with the BTK inhibitor Ibrutinib and Gemcitabine/ Nab-Paclitaxel did not im-
prove outcomes of PDAC patients in comparison to chemotherapy alone in a phase III trial
with 424 participants [57]. A smaller phase II trial (n = 77) investigated the effect of the BTK
inhibitor Acalabrutinib alone or in combination with the PD-1 inhibitor Pembrolizumab in
patients with unresectable or metastatic PDAC who had at least obtained one previous line
of systemic treatment [58]. Again, neither Acalabrutinib alone nor the combination yielded
improvements in mOS (3.6 and 3.8 months, respectively) despite a significant reduction in
granulocytic MDSCs observed in peripheral blood samples in both therapy arms.
Another approach to sensitise PDAC for checkpoint inhibition is the combination
with oncolytic viruses. By inducing selective lysis of tumour cells, oncolytic viruses have
the property to alter the characteristics of immunologically non-accessible tumours. Virus-
induced cell lysis results in increased tumour antigen levels at the site of cell death and
augments invasion and maturation of macrophages and dendritic cells that play a key
role in recruiting and activating T-cells via chemokine secretion, mostly of INF-γ and
TNF-α [59]. Based on this rationale, combinations of tumour vaccines with T-cell based
therapies in xenograft models of melanoma and non-small cell lung cancer [28] or with
immune checkpoint inhibitors in a mouse model of glioblastoma have been evaluated and
resulted in improved survival of animals [60,61]. Additionally, treatment with the oncolytic
reovirus Pelareorep resulted in upregulation of PD-L1 levels in PDAC patients treated in a
phase II clinical trial underscoring the rationale for a combination with immune checkpoint
inhibition [62]. To address this therapeutic approach, a phase Ib clinical trial (n = 11) was
performed evaluating the combination of Pelareorep, the PD-1 antagonist Pembrolizumab
and chemotherapy with 5-FU, Gemcitabine, or Irinotecan [63]. Among patients with
advanced or metastatic PDAC who had obtained one prior line of therapy, a DCR of
3/10 patients was observed resulting in an mOS of 3.1 months. Replicating virus was
detected in most on-treatment biopsy samples. Moreover, treatment significantly increased
levels of multiple chemokines (CXCL9, CXCL10, CXCL11) that are functionally involved in
establishing an immunologically active state by attracting and activating leucocytes. This
therapeutic regimen was further investigated in a phase II trial (NCT03723915). However,
due to data from clinicaltrials.gov this trial did not meet interim analysis criteria for
continuation [64].
As outlined above, Tregs are highly abundant in the TME and peripheral blood of
PDAC patients even at the early stages of the disease and are key players in modulating the
immune response in PDAC [65]. Mechanistically, they mainly suppress INF-γ production
and thus hinder the activation of TIL. However, tumour-suppressing characteristics of
Tregs have also been described [66]. PDAC (and other tumours) secrete high amounts of
cytokines (CCL17; CCL22) which bind to the CC chemokine receptor 4 (CCR4) primarily
expressed on Tregs. Thereby, PDAC cells attract higher numbers of Treg contributing to the
immune suppressed TME [67]. Mogamulizumab is a monoclonal antibody blocking CCR4
and has been approved for the treatment of cutaneous T-cell lymphoma. Clinical evaluation
has revealed a profound reduction of circulating and tumour associated Tregs in tumours
upon treatment with Mogamulizumab in line with preclinical findings [68]. Based on these
data, Mogamulizumab was hypothesised to enhance the effect of checkpoint inhibitors
by facilitating effector T-cell activation in absence of inhibitory Treg. Initial evaluation of
Mogamulizumab in combination with PD-1 inhibition by Nivolumab in advanced solid
tumours (n = 90) in a phase I clinical trial revealed promising results for the PDAC cohort
(15 patients with locally advanced or metastasised PDAC, at least one previous line of
systemic treatment) [69]. In this clinical trial, a DCR of 40% and an mOS of 6.5 months
were observed for combinatorial treatment of the PDAC cohort. While clinical efficacy
did not correlate with PDL-1 or CCR4 expression levels on tumour cells, the number
of TIL or the mutational burden, Mogamulizumab reduced the proportion of Treg and
increased the proportion of CTL in on-treatment biopsies compared to baseline. However,
these findings did not correlate with clinical outcomes. In contrast to these encouraging
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findings, data from a second phase I trial investigating Mogamulizumab in combination
with the CTLA-4 inhibitor Tremelimumab or PD-L1 inhibitor Durvalumab yielded no
convincing antitumour efficacy in various solid tumours including a PDAC expansion
cohort (ORR 0%) (n = 24). However, an effective reduction of tumour-infiltrating Tregs in
post-treatment biopsies compared to baseline could be monitored [70]. Overall, these data
suggest that despite an effective reduction in Tregs and an increase in CTLs in PDAC tissue,
this treatment did not result in pronounced anti-tumour effects and improved survival of
PDAC patients. Furthermore, these results indicate that additional immunosuppressive
mechanisms must be active in PDAC that compromise the efficacy of this therapeutic
approach in this tumour entity.
Another recently explored combinatorial partner for checkpoint inhibition is BL-8040,
a CXC chemokine receptor 4 (CXCR4) antagonist. CXCR4 is abundantly expressed on
leucocytes and signalling via its ligand CXCL12 is functionally involved in chemotaxis and
bone marrow homing of leucocytes. Pharmacological blockade of CXCR4 or abrogation of
its main source CAFs by introducing a diphtheria toxin receptor-expressing Fap transgene
leading to eradication of Fap expressing CAFs upon diphtheria toxin administration in a
mouse model of PDAC altered the composition of the TME and increased T-cell invasion
into the tumour. Furthermore, the combination with PD-1 inhibition resulted in tumour
shrinkage in this mouse model [71]. Additionally, treatment of organotypic slice cultures
from human PDAC specimens with combined BL-8040 and PD-1 inhibition caused a rapid
CTL infiltration of the tumour and induction of tumour cell apoptosis [72]. Based on
these preclinical findings, a phase II clinical was initiated to investigate the combination of
BL-41080, Pembrolizumab and conventional chemotherapy (5-FU, Leucovorin, nanolipo-
somal Irinotecan) in patients with metastatic PDAC who had obtained previous systemic
treatment [73]. Two cohorts were enrolled: Cohort 1 (n = 37) had received one or more
lines of systemic treatment, cohort 2 (n = 22) one previous line with a Gemcitabine-based
regimen. Both cohorts showed a DCR of 34.5% and 77%, respectively. In cohort 2 of
less-heavily pre-treated patients, ORR was 32% and the mean duration of response was
7.8 months. Due to these data showing a promising modest improvement of outcomes,
a clinical investigation is ongoing in a second clinical trial (NCT02907099). Translational
findings from IHC profiling of paired pre- and post-treatment biopsies of 24 PDAC tissues
showed increased infiltration of different T-cell populations, especially activated CD8+
T-cells and decreased numbers of granulocyte-like MDSCs.
Another approach to improve CTL mediated anti-tumour responses in PDAC repre-
sents the combination of the cancer vaccine GVAX (see above) and immune checkpoint
inhibition. To this end, the safety and efficacy of GVAX in combination with the CTLA-4
inhibitor Ipilimumab were evaluated as a maintenance therapy in PDAC patients with
stable disease or ongoing response after 8–12 doses of FOLFIRINOX in comparison to
FOLFIRINOX continuation in a phase II clinical trial [74]. The mean overall survival after
treatment with GVAX and Ipilimumab was 9.38 months compared to 14.7 months after
continuation with FOLFIRINOX. These results indicated no clinical benefit from combined
immunotherapy but clearly favoured FOLFIRINOX continuation for this specific patient
cohort. Interestingly, analysis of peripheral blood comparing baseline to on-treatment
samples revealed reduced numbers of naïve T-cells and increased numbers in T helper
and T effector memory cells after GVAX and Ipilimumab treatment. Moreover, multiplex
IHC of biopsy pairs obtained prior to and on treatment was performed and revealed
a significant increase of CTL upon GVAX and Ipilimumab treatment. However, these
alterations of the PDAC TME did apparently not translate into a clinical benefit, and it
must be assumed that additional immunosuppressive mechanisms are still active in the
TME dampening the activity of the different effector T-cells. In line with this assumption,
treatment with GVAX and Ipilimumab resulted in an upregulation of the immune check-
point T-cell Immunoglobulin and Mucin Domain-3 (TIM-3) in TIL highlighting complex
compensatory mechanisms triggered by this therapeutic intervention [74]. Recently, results
from a second clinical trial investigating the effect of GVAX in combination with immune
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checkpoint inhibition have been published. This phase II clinical trial investigated the
safety and efficacy of GVAX/Cyclophosphamide/CRS-207 with or without additional
Nivolumab (PD-1 inhibitor) in 93 patients with metastatic PDAC. In this patient cohort
who had received one prior line of systemic therapy, the addition of Nivolumab did not
significantly increase overall survival (+Nivolumab 6.1 months mOS versus -Nivolumab
5.9 months mOS) [75]. Multiplex IHC was performed on 22 biopsy pairs obtained prior to
and on treatment identifying a significantly increased density of CD45+ leucocytes and an
increased lymphoid to myeloid cell ratio in patients with long-term survival (>6 months).
Moreover, short-term survivors (<6 months) were characterised by higher IL-6 levels [75].
Additionally, the T-cell repertoire of patients treated with Nivolumab was monitored over
time demonstrating that long term survivors (>6 months) exhibited significantly higher
TCR clonalities after three cycles of treatment than patients with shorter survival [76].
Finally, another approach to potently activate immune responses against PDAC is
combining immune checkpoint inhibition with CD40 agonists. CD40 is a receptor expressed
primarily by DC, B-cells, and myeloid cells. Functionally, CD40 is activated by its ligand
CD40L, which is mostly expressed on CD4+ helper T-cells and mediates the maturation of
DC allowing them to activate CTL [77]. CD40/CD40L interaction is a proximal step in the
activation of DC and B-cells resulting in a plethora of downstream effects. These include the
increased expression of MHC-II and CD86 (a member of the immunoglobulin superfamily
and a co-stimulator for T-cell activation) [78]. Functionally, this allows for increased anti-
gen presentation accompanied by enhanced costimulatory signalling. In the KPC mouse
model, CD40 agonism additionally results in macrophage activation also accompanied
by increased MHC-II and CD86 expression mediating T-cell independent effects. Via in-
creased secretion of CCL2 and INF-γ and elevated expression of matrix metalloproteinases,
macrophages invade and reduce stromal matrix upon CD40 activation [78]. This reversal
of tumour desmoplasia makes CD40 an attractive target for multiple therapeutic strategies
in PDAC. Moreover, macrophages’ direct ability to lyse tumour cells upon CD40 agonist
treatment has been demonstrated in the KPC mouse model [79]. Of note, the combination
of a CD40 agonistic monoclonal antibody with PD-1 or CTLA-4 inhibition synergistically
induced an anti-tumour immune response resulting in tumour regression in another mouse
model of PDAC. This effect was largely reversed by abrogation of CD4+ or CD8+ T-cells
underscoring the important role of effector T-cells in the anti-tumour effect [80].
Based on this rationale, multiple clinical trials have been conducted. First, Beatty
et al. published a small phase I single-arm clinical trial (n = 21) investigating the CD40
agonist Selicrelumab (CP-870,893) in combination with Gemcitabine for the treatment
of chemotherapy-naïve non-operable PDAC. Whilst tolerability was good, 4/21 patients
experienced a partial response and 11/22 stable disease [79]. The resulting mOS of 7.4
months was better than historical controls with Gemcitabine monotherapy (5.7 months).
A recently published phase I clinical trial investigated the CD40 agonistic antibody
Sotigalimab in combination with Gemcitabine/Nab-Paclitaxel with or without additional
Nivolumab for the treatment of therapy-naïve metastatic PDAC (n = 30) [81]. The mOS
across all cohorts was 20.1 months and dual and triple combinations showed a high ORR
ranging between 67% and 83%. Longitudinal collection of blood samples for evaluation of
immune cell populations with flow cytometry revealed an increase in circulating DCs and
multiple T-cell subtypes including activated CD8+ T-cells upon treatment with Sotigalimab
plus chemotherapy. The addition of Nivolumab did not significantly influence these effects.
Based on these promising results in a small patient collective, the randomised phase II
portion of this clinical trial was initiated (NCT03214250). Results presented at the American
Society of Clinical Oncology 2021 annual meeting revealed an overall lower ORR of 33%
and an mOS of 14.5 for Gemcitabine/Nab-Paclitaxel plus Sotigalimab than seen in the
phase I trial and of 10.1 months for the triple combination with additional Nivolumab (ORR
31%) [82]. Interestingly, in this clinical trial Gemcitabine/Nab-Paclitaxel plus Nivolumab
resulted in the best ORR of 50% with an mOS of 16.7 months. Biomarker evaluation is
ongoing and may contribute to the understanding of these results.
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4. Conclusions and Perspectives
Preclinical and clinical data on a plethora of immunotherapy concepts for PDAC
treatment are rapidly mounting. The lack of clinical responses towards a multitude of
immunotherapeutic approaches has again shed light on the specific characteristics of PDAC
as well as the limitations and challenges of transferring innovative research findings into
effective clinical treatment of PDAC patients.
While translation from preclinical models to clinical application is generally difficult,
the lack of novel therapeutics entering the standard of care for PDAC might specifically
highlight the limitations of available preclinical models of PDAC. As PDAC is characterised
by a high proportion of dense tumour stroma and resulting cell–matrix and cell–cell
interactions, meaningful models should allow studying these interactions. Moreover,
patient cohorts subjected to novel treatment strategies have often been treated with at
least one prior line of therapy including repeated drug exposure. Most tumour models
do not recapitulate this characteristic which may significantly shape the response towards
experimental therapeutic agents. Innovative in vitro models, e.g., patient-derived organoid
co-culture models and ex vivo culture of tissue slices may help to overcome some of the
limitations of 2D cell cultures as they enable tumour cell/immune cell interactions in the
presence of experimental drugs and have been demonstrated to recapitulate drug effects
observed in patients [83–85].
Moreover, increasingly ambitious translational research programmes have been devel-
oped that accompany clinical trials and improve the understanding of PDAC immunology
even if clinical endpoints are not met. Ideally, these programmes will result in “reverse
translation” by experimentally establishing concepts to overcome resistance towards im-
munotherapeutic strategies. However, in terms of translational methodology, a lack of
established standards for patient material sampling and methods to evaluate immune
responses becomes apparent. While peripheral blood samples are often collected longitu-
dinally and blood cell populations are assessed by flow cytometry-based assays, only a
subset of clinical trial protocols includes the longitudinal collection of tumour material for
histological evaluation and functional analysis of TIL. This is understandable as tumour
access is anatomically difficult in PDAC patients and repeated sampling is associated with
an imminent risk of complications. However, a comprehensive comparison of pre- and
on- or post-treatment biopsies may substantially improve the understanding of biological
processes in general and in individual patients. Moreover, additional factors such as the
gut and intratumoural microbiomes determine responses to immunotherapy [86,87] and
have to date not been broadly addressed in translational studies. A consensus definition of
standards for the translational investigation of patient samples obtained from clinical trials
investigating immunotherapeutic strategies may help to generate more meaningful data
and decipher the biological processes involved in therapeutic responses.
Summarising the available translational data sets from clinical trials presented in
this review, a recurring pattern of immune response to diverse immunotherapeutic strate-
gies becomes obvious. Multiple clinical trials testing the efficacy of immunotherapeutic
strategies reported decreased Treg numbers or increased T-cell proliferation in peripheral
blood or TME [24,70] or even increased numbers of TIL or CTL [69,75]. However, these
immunogenic alterations rarely translated into meaningful clinical benefit and did not
consistently correlate with improved clinical outcomes [49,74]. These findings highlight
either the existence of additional mechanisms operating concomitantly in the patient and
preventing effective tumour cell identification and eradication by TIL in PDAC or that
the most effective immunosuppressive mechanism has not been targeted in the respec-
tive patient by the evaluated therapeutic approach. Thus, translational research efforts
should aim at comprehensively dissecting the individual immunosuppressive as well as
putative tumour reactive mechanistic arsenal in PDAC patients to improve recognition and
cytolysis of tumour cells by TIL. In this context, Chen and Mellman have introduced the
seminal concept of an immune set point [88]. Briefly, the immune set point is defined as
the situation when stimulatory factors favouring an immune response against cancer cells
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overrule the counteracting inhibitory factors and tumour cells are successfully eradicated
by TIL. The immune set point is determined by tumour intrinsic (mostly genetic and epige-
netic characteristics), host-specific (alleles determining overall immune response towards
immunogenic stimuli), and external factors (microbiome, environmental parameters). The
lacking clinical efficacy of immune therapeutics in PDAC despite induced changes in
immune cell populations indicates their inefficacy in terms of reaching the immune set
point. To date, it remains unresolved which factors mainly hamper the successful immune
response towards PDAC cells. However, a broadened understanding of respective factors
is urgently needed to improve our concepts of PDAC biology in the context of immunother-
apy and exploit it therapeutically in a personalised manner, most likely by combining
multiple immunomodulating agents, adding immunomodulating agents to targeted agents
(e.g., kinase inhibitors) or combining them with tumour stroma modifying agents.
Strikingly, none of the above-mentioned trials selected or stratified patients based
on molecular or immunological criteria. This is surprising, as intra- and inter-tumour
heterogeneity are well-defined characteristics of PDAC [89] and have resulted in extensive
efforts to establish meaningful subtypes based on integrated analysis of genetic, histologi-
cal, and clinical data [90–93]. Additionally, three different states of PDAC immunogenicity
can be defined that partially overlap with the molecular subtypes [94]. (1) The immune
escape phenotype is characterised by high numbers of Treg and M2-macrophages and is
associated with poor prognosis. (2) The immune rich phenotype is characterized by high
numbers of TIL similar to (3) the immune exhausted phenotype. Whilst TIL exert tumour
cell cytotoxicity in the immune rich phenotype, counterregulatory mechanisms (e.g., up-
regulation of immune checkpoints) hamper effective anti-tumour immunity in the immune
exhausted phenotype despite the presence of TIL. Based on gene expression data, PDACs
can also be stratified according to TIL activity into low and high cytolytic tumours [95].
These characteristics are strongly associated with tumour subtypes based on genetic alter-
ations underpinning a strong link between genomic alterations and immune phenotypes in
PDAC [95]. Regarding this complex picture of PDAC biology, a “one-fits-all” therapeutic
approach will probably not yield substantial therapeutic benefits and will likely need to be
replaced by individualised therapeutic concepts based on meaningful biomarkers.
In summary, the extensive efforts to investigate immunotherapeutic strategies for the
treatment of PDAC have resulted in important insights into PDAC immunology and the
plethora of ongoing clinical trials will add to this repository (Table 1). However, the mostly
disappointing clinical results have also highlighted several pitfalls and future tasks for
researchers and clinicians. These are namely (i) the careful choice and development of
preclinical models mimicking best PDAC biology and immunity to ensure translatability
of preclinical findings into meaningful clinical advances, (ii) the need to define standards
for translational evaluation of clinical trials investigating immunotherapeutic treatments
in PDAC to allow more comprehensive analyses of patient materials, (iii) the need to
improve our understanding of the cancer immune cycle and the immune set point in
PDAC (patients) to translationally overcome barriers towards efficient CTL responses, and
(iv) the identification of biomarkers allowing the stratification of patients according to
PDAC (immune) subtypes and study designs that acknowledge PDAC tumour (and host)
heterogeneity. Consideration of these aspects will hopefully improve immunotherapeutic
treatment and survival of PDAC patients as already achieved in other cancer entities.
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Abbreviations
APC Antigen presenting cell
BTK Bruton Tyrosine Kinase
CAF Carcinoma associated fibroblasts
CD40 Cluster of Differentiation 40
CTL Cytotoxic T lymphocytes
CTLA-4 Cytotoxic T-Lymphocyte-Associated Protein 4
DCR Disease control rate
ECM Extracellular matrix
FOLFIRINOX 5-FU, Irinotecan, Leucovorin, Oxaliplatin
5-FU 5-Fluorouracil
GM-CSF Granulocyte-Macrophage Colony Stimulating Factor
ICOS Inducible T-cell costimulator kinase inhibition
IHC immunohistochemistry
INF-γ Interferon-gamma
KIF20A Kinesine-like Protein KIF 20A
MDSC Myeloid derived suppressor cells
mOS Mean overall survival
ORR Overall response rate
PD-1 Programmed cell death protein 1
PDAC Pancreatic ductal adenocarcinoma
PD-L1 Programmed cell death 1 ligand 1
STING Stimulator of interferon genes
TAM Tumour-associated macrophages
TCR T-cell receptor
TGF-β Transforming Growth Factor-beta
TIL Tumour infiltrating lymphocytes
TME Tumour microenvironment
Treg regulatory T-cells
VEGFR Vascular Endothelial Growth Factor Receptor
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